Today: 21 July 2026
Browse Category

Pharmaceutical Industry 24 December 2025 - 6 January 2026

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Travere Therapeutics TVTX stock slides 5% as FDA decision on Filspari nears

Nasdaq-listed Travere Therapeutics shares fell 5.3% to $36.09 in afternoon trading on Tuesday as investors looked toward next week’s U.S. FDA decision deadline on expanding its kidney drug Filspari into focal segmental glomerulosclerosis. The FDA’s Prescription Drug User Fee Act, or PDUFA, target action date is Jan. 13, and the stock has ranged from $34.88 to $39.16 in the session. SEC
6 January 2026
··
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics shares jumped about 23% in the most recent session on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental application for AXS-05 to treat agitation in Alzheimer’s disease and granted the filing priority review. The stock last traded at $182.64, after swinging between $148.79 and $184.40 on volume of about 3.1 million shares. Businessinsider
1 January 2026
···
Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly and Company heads into the final two trading days of 2025 with U.S. markets closed for the weekend and investors weighing a familiar mix of catalysts: the booming obesity-drug franchise, the intensifying race to bring weight-loss pills to market, and fast-evolving policy and pricing dynamics that could reshape demand. Reuters+2Reuters+2
28 December 2025
·
AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Inc. heads into the weekend with Wall Street shut and year-end positioning in full swing, after a quiet, post-holiday session on Friday left major U.S. indexes essentially unchanged. In thin trading, investors continue to weigh two competing narratives: a strong 2025 for equities and the seasonally bullish “Santa Claus rally” window — versus the reality that year-end liquidity can amplify moves on any surprise headline. Reuters
27 December 2025
···
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Inc. is heading into the final trading days of 2025 with its stock still anchored in the mid-$20s, a range that has increasingly defined sentiment around the pharmaceutical giant as Wall Street debates two competing narratives: near-term pressure from fading COVID-era revenues and patent expirations, versus a longer-term rebuild driven by oncology and newer growth categories such as obesity.
27 December 2025
···
Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

Wave Life Sciences (WVE) Stock Today: Obesity Drug Catalyst, $402.5M Financing, and What Investors Are Watching Next

New York, Dec. 26, 2025 — Wave Life Sciences Ltd. is trading at $18.12, down about 0.74% in the late morning session. The move comes while biotech is broadly softer—SPDR S&P Biotech ETF is down about 1.07% and iShares Nasdaq Biotechnology ETF is down about 0.63%—even as the broader market edges higher, with SPY and QQQ both modestly in the green.
26 December 2025
··
1 … 3 4 5 6 7 … 10
Go toTop